"The fact that it was a simple blood test, it was absolutely objective, and it was…non-invasive…made it very attractive," says William J. Catalona, MD.
As part of the Urology Times' 50th Anniversary Innovation Celebration, William J. Catalona, MD, discusses how prostate-specific antigen (PSA) testing has greatly impacted the field of urology over the past 50 years. Catalona is a professor of urology at Northwestern University in Chicago, Illinois.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.